Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
2.

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.

Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Review. French.

3.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. No abstract available.

PMID:
28923215
4.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

5.

Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.

Borchiellini D, Etienne-Grimaldi MC, Bensadoun RJ, Benezery K, Dassonville O, Poissonnet G, Llorca L, Ebran N, Formento P, Château Y, Thariat J, Milano G.

Oral Oncol. 2017 Apr;67:70-76. doi: 10.1016/j.oraloncology.2017.02.003. Epub 2017 Feb 14.

PMID:
28351583
6.

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; French National Network of Pharmacogenetics (RNPGx).

Therapie. 2017 Apr;72(2):185-192. doi: 10.1016/j.therap.2016.09.014. Epub 2017 Jan 30. Review.

PMID:
28237406
7.

Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx).

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; Réseau national de pharmacogénétique (RNPGx).

Therapie. 2017 Apr;72(2):175-183. doi: 10.1016/j.therap.2016.09.007. Epub 2017 Jan 3. French. No abstract available.

PMID:
28153355
8.

Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.

Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E.

Clin Pharmacokinet. 2017 Feb;56(2):165-177. doi: 10.1007/s40262-016-0431-2.

PMID:
27393140
9.

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.

Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, Bidard FC, Rodrigues M, Plancher C, Mariani P, Cassoux N, Decaudin D, Asselain B, Servois V.

Oncologist. 2016 Mar;21(3):281-2. doi: 10.1634/theoncologist.2015-0501. Epub 2016 Feb 24.

10.

Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.

Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G.

Laryngoscope. 2016 Apr;126(4):E156-63. doi: 10.1002/lary.25754. Epub 2015 Nov 24.

PMID:
26597440
11.

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.

Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx).

Fundam Clin Pharmacol. 2015 Jun;29(3):219-37. doi: 10.1111/fcp.12117. Epub 2015 May 4.

PMID:
25817555
12.

Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.

Veracini L, Grall D, Schaub S, Beghelli-de la Forest Divonne S, Etienne-Grimaldi MC, Milano G, Bozec A, Babin E, Sudaka A, Thariat J, Van Obberghen-Schilling E.

Oncotarget. 2015 Apr 10;6(10):7570-83.

13.

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.

Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, Laurent-Puig P.

Cancer Med. 2015 Mar;4(3):371-82. doi: 10.1002/cam4.370. Epub 2015 Feb 2.

14.

Frequent intragenic rearrangements of DPYD in colorectal tumours.

van Kuilenburg AB, Etienne-Grimaldi MC, Mahamat A, Meijer J, Laurent-Puig P, Olschwang S, Gaub MP, Hennekam RC, Benchimol D, Houry S, Letoublon C, Gilly FN, Pezet D, Andre T, Faucheron JL, Abderrahim-Ferkoune A, Vijzelaar R, Pradere B, Milano G.

Pharmacogenomics J. 2015 Jun;15(3):211-8. doi: 10.1038/tpj.2014.68. Epub 2014 Oct 28.

PMID:
25348620
15.

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Loriot MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C.

Bull Cancer. 2014 Jun;101(6):533-53. doi: 10.1684/bdc.2014.1933. Review. French.

PMID:
24977443
16.

Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.

Peters GJ, Honeywell RJ, Maulandi M, Giovannetti E, Losekoot N, Etienne-Grimaldi MC, Milano G, Serdjebi C, Ciccolini J; EORTC-Pharmacology and Molecular Mechanism Group.

Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):403-12. doi: 10.1080/15257770.2014.894196.

PMID:
24940698
17.

Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.

Etienne-Grimaldi MC, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, Formento JL, Formento P, Sudaka A, Boige V, Abderrahim-Ferkoune A, Benchimol D, André T, Houry S, Faucheron JL, Letoublon C, Gilly FN, Delpero JR, Lasser P, Pradere B, Pezet D, Penault-Llorca F, Milano G.

Br J Cancer. 2014 May 27;110(11):2728-37. doi: 10.1038/bjc.2014.213. Epub 2014 May 6.

18.

High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression.

Doyen J, Letouzé E, Marisa L, de Reyniès A, Milano G, Etienne-Grimaldi MC, Olschwang S, Gaedcke J, Ghadimi M, Gérard JP.

Strahlenther Onkol. 2014 Oct;190(11):1028-36. doi: 10.1007/s00066-014-0659-4. Epub 2014 Apr 26.

PMID:
24770938
19.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I.

J Clin Oncol. 2014 Apr 1;32(10):1031-9. doi: 10.1200/JCO.2013.51.1857. Epub 2014 Mar 3. Review.

20.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

21.

Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.

Francois E, Bennouna J, Chamorey E, Etienne-Grimaldi MC, Renée N, Senellart H, Michel C, Follana P, Mari V, Douillard JY, Milano G.

Chemotherapy. 2012;58(5):371-80. doi: 10.1159/000343969. Epub 2012 Dec 11.

PMID:
23235319
22.

Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).

Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, Grall D, Penault-Llorca F, Dassonville O, Bertucci F, Cayre A, De Raucourt D, Geoffrois L, Finetti P, Giraud P, Racadot S, Morinière S, Sudaka A, Van Obberghen-Schilling E, Milano G.

Clin Cancer Res. 2012 Sep 15;18(18):5123-33. Epub 2012 Aug 1.

23.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.

PMID:
22714791
24.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17.

PMID:
22608542
25.

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C, Jacob JH, Milano G.

Br J Clin Pharmacol. 2012 May;73(5):776-85. doi: 10.1111/j.1365-2125.2011.04141.x.

26.

The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes.

Borchiellini D, Etienne-Grimaldi MC, Thariat J, Milano G.

Cancer Treat Rev. 2012 Oct;38(6):737-59. doi: 10.1016/j.ctrv.2012.02.004. Epub 2012 Mar 2. Review.

PMID:
22387145
27.

Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture.

Thariat J, Etienne-Grimaldi MC, Grall D, Bensadoun RJ, Cayre A, Penault-Llorca F, Veracini L, Francoual M, Formento JL, Dassonville O, De Raucourt D, Geoffrois L, Giraud P, Racadot S, Morinière S, Milano G, Van Obberghen-Schilling E.

Clin Cancer Res. 2012 Mar 1;18(5):1313-22. doi: 10.1158/1078-0432.CCR-11-2339. Epub 2012 Jan 6.

28.

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.

Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, Milano G.

BMC Cancer. 2011 Nov 25;11:496. doi: 10.1186/1471-2407-11-496.

29.

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.

Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, Jego G, Wanherdrick K, Joly AL, Buhard O, Gobbo J, Penard-Lacronique V, Zouali H, Tubacher E, Kirzin S, Selves J, Milano G, Etienne-Grimaldi MC, Bengrine-Lefèvre L, Louvet C, Tournigand C, Lefèvre JH, Parc Y, Tiret E, Fléjou JF, Gaub MP, Garrido C, Duval A.

Nat Med. 2011 Sep 25;17(10):1283-9. doi: 10.1038/nm.2457.

PMID:
21946539
30.

Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.

Bozec A, Sudaka A, Etienne-Grimaldi MC, Brunstein MC, Fischel JL, Milano G.

Oral Oncol. 2011 Oct;47(10):940-5. doi: 10.1016/j.oraloncology.2011.07.028. Epub 2011 Sep 8.

PMID:
21862388
31.

Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.

Thariat J, Etienne-Grimaldi MC, Launay-Vacher V, Soto-Matos A, Fernandez-Teruel C, Ghafari T, Marcy PY, Milano G, Renée N, Gastaud L, Thyss A.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1363-7. doi: 10.1007/s00280-011-1718-5. Epub 2011 Aug 18.

PMID:
21850465
32.

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27.

PMID:
21795074
33.

The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P, Milano G.

Oral Oncol. 2011 May;47(5):340-4. doi: 10.1016/j.oraloncology.2011.02.020. Epub 2011 Mar 21.

PMID:
21421338
34.

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.

Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q.

Clin Cancer Res. 2011 Mar 15;17(6):1632-40. doi: 10.1158/1078-0432.CCR-10-2169. Epub 2011 Jan 28. Review.

35.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, Espié M, Veyret C, Formento JL, Francoual M, Piutti M, de Crémoux P, Milano G.

Br J Clin Pharmacol. 2011 Jun;71(6):921-8. doi: 10.1111/j.1365-2125.2010.03896.x.

36.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
37.

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.

van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC, Klümpen HJ, Maring JG, Derleyn VA, Maartense E, Milano G, Vijzelaar R, Gross E.

Hum Genet. 2010 Nov;128(5):529-38. doi: 10.1007/s00439-010-0879-3. Epub 2010 Aug 29.

38.

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY.

Ann Oncol. 2010 Sep;21(9):1765-71. doi: 10.1093/annonc/mdq052. Epub 2010 Mar 16.

PMID:
20233745
39.

Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.

Bozec A, Formento P, Fischel JL, Etienne-Grimaldi MC, Milano G.

Oral Oncol. 2010 Mar;46(3):172-7. doi: 10.1016/j.oraloncology.2009.11.010. Epub 2010 Feb 13.

PMID:
20156700
40.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A.

Br J Clin Pharmacol. 2010 Jan;69(1):58-66. doi: 10.1111/j.1365-2125.2009.03556.x.

41.

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.

Etienne-Grimaldi MC, Renée N, Izzedine H, Milano G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3757-61. doi: 10.1016/j.jchromb.2009.09.011. Epub 2009 Sep 17.

PMID:
19797000
42.

Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer.

Formento JL, Etienne-Grimaldi MC, Francoual M, Pagès G, Onesto C, Formento P, Chamorey E, Dassonville O, Poissonnet G, Milano G.

Pharmacogenomics. 2009 Aug;10(8):1277-83. doi: 10.2217/pgs.09.54.

PMID:
19663672
43.

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.

Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G.

Ann Oncol. 2009 Oct;20(10):1703-7. doi: 10.1093/annonc/mdp070. Epub 2009 Jun 19.

PMID:
19542251
44.

Impact of erythropoietin on the effects of irradiation under hypoxia.

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.

PMID:
19499245
45.

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.

Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28.

46.

Pharmacokinetics of sunitinib in hemodialysis.

Izzedine H, Etienne-Grimaldi MC, Renée N, Vignot S, Milano G.

Ann Oncol. 2009 Jan;20(1):190-2. doi: 10.1093/annonc/mdn626. Epub 2008 Sep 18. No abstract available.

PMID:
18801884
47.

Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis.

Thariat J, Azzopardi N, Peyrade F, Launay-Vacher V, Santini J, Lecomte T, Etienne-Grimaldi MC, Paintaud G, Milano G.

J Clin Oncol. 2008 Sep 1;26(25):4223-5. doi: 10.1200/JCO.2008.18.7674. No abstract available. Erratum in: J Clin Oncol. 2008 Dec 20;26(36):6021.

PMID:
18757343
48.

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.

Bozec A, Gros FX, Penault-Llorca F, Formento P, Cayre A, Dental C, Etienne-Grimaldi MC, Fischel JL, Milano G.

Eur J Cancer. 2008 Sep;44(13):1922-30. doi: 10.1016/j.ejca.2008.07.013. Epub 2008 Aug 6.

PMID:
18691881
49.

Nuclear localization of a novel human syntaxin 1B isoform.

Pereira S, Massacrier A, Roll P, Vérine A, Etienne-Grimaldi MC, Poitelon Y, Robaglia-Schlupp A, Jamali S, Roeckel-Trevisiol N, Royer B, Pontarotti P, Lévêque C, Seagar M, Lévy N, Cau P, Szepetowski P.

Gene. 2008 Nov 1;423(2):160-71. doi: 10.1016/j.gene.2008.07.010. Epub 2008 Jul 17.

PMID:
18691641
50.

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G.

Clin Cancer Res. 2008 Aug 1;14(15):4830-5. doi: 10.1158/1078-0432.CCR-07-4906.

Supplemental Content

Loading ...
Support Center